1. Bristol-Myers Squibb’s Opdivo received its eighth indication. The immuno-oncology drug received accelerated approval from the FDA to treat classical Hodgkin lymphoma.
2. The U.S. Patent and Trademark Office took up a petition filed by Coherus BioSciences to review a key patent for AbbVie’s Humira. Coherus plans to file its biosimilar version of Humira with the FDA later this year. (WSJ)
3. AstraZeneca CEO Pascal Soriot said that the drugmaker has had “too much stability” in the past. “We had people who never moved and turnover of one or two percent. That might sound good, but it’s actually not, because you don’t have new ideas flowing through the place.” (Reuters)
4. The British drugmaker, too, said Tuesday that it plans to file its new injectable asthma drug, benralizumab, with U.S. and European regulators in the second half of this year. The drug is expected to compete with GlaxoSmithKline’s Nucala and Teva Pharmaceutical Industries’ Cinqair. (FT)
5. Walmart wants to be the “front door” of U.S. healthcare. George Riedl, the company’s president of health and wellness, said Walmart has an opportunity “to own this space.” (Chain Drug Review)